PEG-MGF (Pegylated Mechano Growth Factor)

PEG-MGF, or Pegylated Mechano Growth Factor, is a synthetic analog of Mechano Growth Factor (MGF), a splice variant of the Insulin-Like Growth Factor 1 (IGF-1). MGF is naturally released in response to muscle damage or intense physical activity, where it plays an important role in muscle repair and growth by activating satellite cells. PEG-MGF has been modified through a process called pegylation, which extends its half-life, allowing it to remain in the body longer for sustained effects. PEG-MGF is primarily used for muscle recovery, tissue repair, and lean muscle growth.

Category

Growth Factor Peptide

Sequence

PEG-Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys

Molecular Weight

Approximately 2867.2 g/mol

Molecular Formula

C121H200N42O39

Half Life

Approximately 48–72 hours

Most Common Uses

PEG-MGF is a synthetic peptide primarily used in research and experimental settings to promote muscle repair and growth. It is frequently investigated for its potential to enhance muscle recovery following injury or intense exercise, as it stimulates satellite cell activation and protein synthesis in skeletal muscle. PEG-MGF is also explored in studies addressing muscle-wasting conditions, such as sarcopenia or cachexia, aiming to preserve muscle mass and strength in aging or chronically ill patients. In sports science, it attracts interest for its ability to accelerate tissue regeneration, often administered post-workout to support hypertrophy and repair in preclinical models. These applications highlight PEG-MGF’s role in advancing muscle repair therapies, though its use remains largely experimental pending further clinical validation.

Mechanism of Action

PEG-MGF functions by promoting muscle repair and growth through its interaction with cellular pathways. Derived from the insulin-like growth factor-1 (IGF-1) gene, it is produced in response to mechanical stress or muscle damage and acts locally to stimulate satellite cell proliferation and differentiation. This process facilitates muscle fiber regeneration by enhancing protein synthesis and inhibiting protein breakdown. PEG-MGF binds to specific receptors on muscle cells, activating signaling cascades that promote myoblast fusion and hypertrophy. It supports tissue repair in preclinical studies, making it a promising candidate for muscle-wasting disorders and injury recovery. Its targeted mechanism underscores its potential in advancing regenerative therapies, though further research is needed to fully establish clinical applications.

Structure and Pharmacology

PEG-MGF is a synthetic peptide derived from the insulin-like growth factor-1 (IGF-1) gene. This 24-amino-acid structure is conjugated to polyethylene glycol (PEG), which enhances its stability and extends its activity in the body. With a molecular weight of approximately 2867.2 g/mol (core peptide, varying with PEG size) and a molecular formula of C121H200N42O39, PEG-MGF’s design allows it to interact effectively with muscle cell receptors. The PEGylation protects the peptide from rapid degradation, enabling prolonged therapeutic effects compared to native MGF.

Pharmacologically, it acts by binding to receptors on muscle cells, stimulating satellite cell activation and proliferation, which enhances muscle fiber regeneration and hypertrophy. This mechanism supports tissue repair in conditions like muscle injury or wasting disorders such as sarcopenia. The pegylation extends its half-life to approximately 48–72 hours, allowing less frequent dosing compared to native MGF’s short 5–7-minute duration. PEG-MGF is metabolized primarily in the liver and kidneys, with clearance through standard peptide degradation pathways. Its targeted action minimizes systemic effects, though careful monitoring is needed to manage potential side effects like mild injection-site reactions or temporary water retention in experimental applications.

Dosages

PEG-MGF is typically administered through subcutaneous or intramuscular injections in research settings to support muscle repair and growth. Doses commonly range from 100 to 400 micrograms per administration, often given two to three times weekly, depending on the study protocol or therapeutic goal, such as muscle recovery or treatment of muscle-wasting conditions. In preclinical models targeting muscle injury, single doses may be timed post-exercise to maximize satellite cell activation and tissue regeneration.

The peptide’s extended half-life allows less frequent dosing compared to native MGF, ensuring sustained activity. Researchers adjust dosages based on patient weight, typically 1–5 micrograms per kilogram, to optimize efficacy while minimizing side effects like mild swelling or discomfort at the injection site.

Warnings and Cautions

PEG-MGF requires cautious use in research settings due to its potent effects on muscle growth and limited clinical data. It may cause mild side effects, such as localized swelling, redness, or discomfort at the injection site, and some users report temporary fatigue or joint stiffness. Excessive dosing could overstimulate muscle satellite cells, potentially leading to abnormal tissue growth or inflammation, particularly in those with pre-existing musculoskeletal conditions. Patients with liver or kidney impairments need careful monitoring, as PEG-MGF’s metabolism relies on these organs.

Allergic reactions, though rare, may occur, necessitating immediate discontinuation if symptoms like rash or swelling appear. Long-term effects remain understudied, so prolonged use should be approached cautiously, especially in non-clinical contexts like athletic performance enhancement. Precise dosing, typically 100–500 micrograms per administration, and medical supervision are essential to ensure safety and minimize risks in experimental applications.

Research & Clinical Trials

Promotes Neurogenesis in the Aging Brain

Full-Length MGF Activates IGF-I Receptor at High Concentrations

The study concluded that full-length MGF is able to directly activate the IGF-I receptor (IGF-IR), as well as the insulin receptors IR-A and IR-B, although it does so less efficiently than their natural ligands at low concentrations. Specifically, full-length MGF required higher concentrations (higher EC50) to activate IGF-IR compared to IGF-I, but at high concentrations it achieved a similar maximal activation as IGF-I. For insulin receptors, full-length MGF could also activate IR-A to the same maximal level as insulin, and it was even more potent than insulin in stimulating IR-B at high concentrations.

Sourcing

USA

LIMITLESS LIFE NOOTROPICS aka Biotech

Use Discount Code: EP20

SCANTIFIX

Use Discount Code: Exploringpeptides

Canada

BIOSLAB

Use Discount Code: EP10

Europe

DNLABResearch

Use Discount Code: EP15

Australia

LVLUPHEALTH

References

[1] Tang, J.J., Podratz, J.L., Lange, M. et al. Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain. Mol Brain 10, 23 (2017). https://doi.org/10.1186/s13041-017-0304-0

[2] Janssen, J. A. M. J. L., Hofland, L. J., Strasburger, C. J., van den Dungen, E. S. R., & Thevis, M. (2016). Potency of full-length MGF to induce maximal activation of the IGF-I R is similar to recombinant human IGF-I at high equimolar concentrations. PLOS ONE, 11(3), e0150453. https://doi.org/10.1371/journal.pone.0150453

Related articles

Sermorelin Guide: Benefits, Side Effects, Dosage & More

SLU-PP-915: Benefits, Research & Comparison with SLU-PP-332

Adalank vs Selank: Differences, Benefits and Effects

Adamax vs Semax: Comparison, Benefits, and Effects

Common Mistakes When Reconstituting Peptides

Peptides Vs Proteins: What’s The Difference?